{"id":"W4366496702","doi":"10.1016/j.ejca.2023.04.007","title":"Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Boehringer Ingelheim","keywords":"Afatinib; Refractory (planetary science); Medicine; Oncology; Internal medicine; Pediatrics; Cancer; Gefitinib; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001643541,0.0007120907,0.001746436,0.0001373041,0.0002386245,0.0006216437,0.0005476382,0.0006101397,0.001378804],"category_scores_gemma":[0.001239774,0.0002046062,0.0009778314,0.000388079,0.0005180044,0.0005483914,0.0002801148,0.002389983,0.0003895322],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009491578,"about_ca_system_score_gemma":0.001277103,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001174783,"about_ca_topic_score_gemma":0.002083692,"domain_scores_codex":[0.9994401,0.0002884929,0.00005383672,0.00007179157,0.00007620339,0.00006945628],"domain_scores_gemma":[0.9991628,0.0001475366,0.0002440739,0.0000897018,0.000104311,0.000251639],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3071621,0.02498458,0.05290309,0.003309238,0.003296214,0.003678259,0.001766813,0.008443337,0.1392599,0.0007502846,0.012373,0.4420732],"study_design_scores_gemma":[0.2885743,0.5173694,0.1225554,0.0003253091,0.001820967,0.01092065,0.0003713553,0.003400146,0.02660876,0.0004555928,0.02750385,0.00009420536],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923422,0.00478234,0.0004951472,0.0003181545,0.00003938258,0.0005549522,0.0005083568,0.00004159063,0.0009178867],"genre_scores_gemma":[0.9903234,0.004219405,0.002269158,0.0003931133,0.00006358798,0.0005432605,0.001503939,0.00002946093,0.0006545602],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001746436,"threshold_uncertainty_score":0.008691967,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04850224767936248,"score_gpt":0.3747968129093108,"score_spread":0.3262945652299483,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}